Literature DB >> 6741983

Clinical and microbial features of prosthetic joint infection.

R D Inman, K V Gallegos, B D Brause, P B Redecha, C L Christian.   

Abstract

A one-year experience with prosthetic joint infection, in which 63 cases were identified, is reviewed. Thirty cases (48 percent) were early infections, in the first postoperative year, and 33 cases (52 percent) were late, occurring more than one year after implantation. Pain was the predominant symptom, but clinical clues suggesting infection were frequently absent, with fever in 43 percent and leukocytosis in only 10 percent. The radiographic appearance was more frequently abnormal in late infections (67 versus 37 percent, p less than 0.02). Staphylococci were predominant organisms, constituting 59 percent of prosthetic joint infections, and S. epidermidis was the predominant species in both early and later infections. Of the hematogenous infections, 11 of 13 occurred in the group with late infections; these were mostly nonstaphylococcal . Antigenic proteins of S. epidermidis were characterized by gel electrophoresis, but no infection-specific antigens could be identified when patient serum was compared with normal samples. Precipitating antibodies to the extracellular proteins of S. epidermidis were present in 50 percent of patients with S. epidermidis prosthetic joint infections, 27 percent of patients with nonstaphylococcal infections, 20 percent of patients with S. aureus infections, and 11 percent of normal subjects. In view of the increasing importance of prosthetic joint infection, further study of the pathogenesis of the infection and the host immune response is warranted.

Entities:  

Mesh:

Year:  1984        PMID: 6741983     DOI: 10.1016/0002-9343(84)90434-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  32 in total

1.  Use of light handles in the laminar flow operating theatre--is it a cause of bacterial concern?

Authors:  J R Hussein; R N Villar; A J Gray; M Farrington
Journal:  Ann R Coll Surg Engl       Date:  2001-09       Impact factor: 1.891

2.  An infected prosthetic hip. Is there a role for prophylactic antibiotics?

Authors:  J C Mason; C T Dollery; A So; J Cohen; S R Bloom; C Bulpitt; R Russell-Jones; C M Oakley
Journal:  BMJ       Date:  1992-08-01

3.  Treatment Options for Orthopedic Device-related Infections.

Authors:  Edna Toubes; John Segreti
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

4.  Corynebacterium species isolated from bone and joint infections identified by 16S rRNA gene sequence analysis.

Authors:  Véronique Roux; Michel Drancourt; Andreas Stein; Philippe Riegel; Didier Raoult; Bernard La Scola
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

5.  [The infected implant. Part 1: bacteriology].

Authors:  U Geipel; M Herrmann
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

6.  Surface modification of biomaterials using plasma immersion ion implantation and deposition.

Authors:  Tao Lu; Yuqin Qiao; Xuanyong Liu
Journal:  Interface Focus       Date:  2012-03-21       Impact factor: 3.906

7.  Attachment of Staphylococcus aureus to polymethylmethacrylate increases its resistance to phagocytosis in foreign body infection.

Authors:  P E Vaudaux; G Zulian; E Huggler; F A Waldvogel
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  Current concepts in the management of infections in bones and joints.

Authors:  A S Dickie
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

9.  Differential Expression of Lipoxygenase Isoenzymes in Embryos of Germinating Barley.

Authors:  W. L. Holtman; G. Van Duijn; NJA. Sedee; A. C. Douma
Journal:  Plant Physiol       Date:  1996-06       Impact factor: 8.340

10.  Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.

Authors:  M Drancourt; A Stein; J N Argenson; A Zannier; G Curvale; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.